JUN 14, 2019 11:18 AM PDT

Attaching a removable lock to an arthritis drug

WRITTEN BY: Nouran Amin

A study published in PLOS Biology suggests that attaching a removable lock to an arthritis drug can increase its effectiveness. The study sheds new light on a drug taken by millions of patients throughout the world.

Learn more about rheumatoid arthritis:

Arthritis drugs, like the monoclonal antibodies infliximab and adalimumab, have been considered breakthrough treatments for their ability to target and inhibit the activity of tumor necrosis factor alpha (TNF-alpha)—which is a key signaling molecule in the autoimmune cascade. However, the use of TNF-alpha blockers has major disadvantages. For one, their use can result in immune suppression. To mitigate the problem, researchers added a removable protein "lock" to the infliximab antibody.

The lock was attached chemically to the active site of the antibody via a protein tag that can be removed by an enzyme called matrix metalloproteinase (MMP).

MMP’s are abundant at the site of rheumatoid arthritis and is implicated in the characteristic tissue breakdown seen in the disease. Therefore, researchers were hopeful that at the site of the disease—and not in inactive in non-arthritic tissues--the high concentrations of MMP would remove the lock and release the active infliximab primarily at the site of disease, while leaving it largely locked and inactive in non-arthritic tissues where MMP levels were lower. Additionally, the researchers hoped that the presence of a lock would alter the shape of the infliximab enough to prevent any anti-infliximab antibodies from developing.

The lock was found to be effective both respects. "The addition of this reversible lock to infliximab has the potential to improve the risk/benefit ratio for patients with rheumatoid arthritis," said lead author of the study, Wen-Wei Lin of Kaohsiung Medical University, Taiwan, "and may serve as a model for improvement of other monoclonal antibody therapies as well. Significant further work will be required before the modified form of the antibody can be tested in a clinical trial in patients”.

Source: Science Daily

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAY 02, 2022
Cell & Molecular Biology
Pipette Matchmaker: Tip Compatibility Like Never Before
MAY 02, 2022
Pipette Matchmaker: Tip Compatibility Like Never Before
Article Written by John Winsor All lab workers have to do it, shifting countless stacks of indiscernible boxes to f ...
APR 20, 2022
Microbiology
Rapid AST: A key weapon in the fight against AMR
APR 20, 2022
Rapid AST: A key weapon in the fight against AMR
Despite the dire, well-documented risks of antimicrobial resistance (AMR), which threatens to kill 10 million people a y ...
MAY 19, 2022
Drug Discovery & Development
Experimental Drug Shows Promise Against ALS
MAY 19, 2022
Experimental Drug Shows Promise Against ALS
A new experimental drug known as NU-9 may be more effective in treating ALS than existing FDA-approved drugs. The corres ...
MAY 26, 2022
Cannabis Sciences
Cannabis Crystal Polymorphism
MAY 26, 2022
Cannabis Crystal Polymorphism
A new published commentary in the Journal of Cannabis Research indicated that cannabis crystallinity may determine level ...
JUN 27, 2022
Drug Discovery & Development
Potential Gene Targets Identified for Treating Deafness
JUN 27, 2022
Potential Gene Targets Identified for Treating Deafness
Researchers have identified three mutations of the MINAR2 gene that are linked to deafness. They say that the mutations ...
JUL 01, 2022
Drug Discovery & Development
Paper-thin Device Treats Pain and then Dissolves in Body
JUL 01, 2022
Paper-thin Device Treats Pain and then Dissolves in Body
Researchers have developed a biocompatible, implantable device that relieves pain and harmlessly dissolves when no longe ...
Loading Comments...